Combination effect of TZT-1027 (Soblidotin) with other anticancer drugs

Anticancer Research

Volumn 26, Issue 2 A, 2006, Pages 1145-1151

  Natsume, Tsugitaka ^a   Watanabe, Jun Ichi ^a   Horiuchi, Toshi ^a   Kobayashi, Motohiro ^a  

^a Grelan Pharmaceutical Co Ltd   (Japan)

Author keywords

A549 non small cell lung carcinoma; Antimicrotubule drug; P388 leukemia; Soblidotin; TZT 1027

Indexed keywords

AURISTATIN PE; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IRINOTECAN; PACLITAXEL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA P 388; LUNG NON SMALL CELL CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; FLUOROURACIL; HUMANS; LEUKEMIA P388; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGOPEPTIDES; PACLITAXEL; TAXOIDS;

EID: 33645825442     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Miyazaki K, Kobayashi M, Natsume T, Gondo M, Mikami T, Sakakibara K and Tsukagoshi S: Synthesis and antitumor activity of novel dolastatin 10 analogs. Chem Pharm Bull 43: 1706-1718, 1995.
2. Kobayashi M, Natsume T, Tamaoki S, Watanabe J, Asano H, Mikami T, Miyasaka K, Miyazaki K, Gondo M, Sakakibara K and Tsukagoshi S: Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. Jpn J Cancer Res 88: 316-327, 1997.
3. Natsume T, Koh Y, Kobayashi M, Fukumoto H, Takahashi F, Nakamura T, Ohe Y, Saijo N and Nishio K: Enhanced antitumor activities of TZT-1027 against TNF-α or IL-6 secreting Lewis lung carcinoma in vivo. Cancer Chemother Pharmacol 49: 35-47, 2002.
4. Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K and Kobayashi M: Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin. Jpn J Cancer Res 91: 737-747, 2000.
5. Watanabe J, Natsume T, Fujio N, Miyasaka K and Kobayashi M: Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 5: 345-353, 2000.
6. Otani M, Natsume T, Watanabe J, Kobayashi M, Murakoshi M, Mikami T and Nakayama T: TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 91: 837-844, 2000.
7. Kobayashi M, Natsume T, Watanabe J, Fujio N, Mikami T, Miyazaki K and Tsukagoshi S: Activity of a novel antitumor agent, TZT-1027. Nippon Yakurigaku Zasshi (Japanese) 114 Suppl: 230P-235P, 1999.
8. Ogawa T, Mimura Y, Isowa K, Kato H, Mitsuishi M, Toyoshi T, Kuwayama N, Morimoto H, Murakoshi M and Nakayama T: An antimicrotubule agent, TZT-1027, does not induce neuropathologic alterations which are detected after administration of vincristine or paclitaxel in animal models. Toxicol Lett 121: 97-106, 2001.
9. Niitani H, Hasegawa K, Furuse K, Fukuoka M, Horikoshi N and Kudoh S: Phase I studies of TZT-1027, a novel inhibitor of tubulin polymerization [abstract 360]. Proc 10th NCI-EORTC Symposium on New Drugs in Cancer Therapy, 1998.
10. Horti J, Juhasz E and Bodrogi I: Preliminary results of a phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer [abstract 2744]. Proc Am Assoc Cancer Res, 2002.
11. Horti J, Juhasz E, Bodrogi I and Ikeda S: A phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC) [abstract 256]. Proc AACR-NCI-EORTC International Conference, Molecular Targets and Cancer Therapeutics, 2003.
12. Yamamoto N, Andoh M, Kawahara M, Fukuoka M and Niitani H: Phase I study of TZT-1027, an inhibitor of tubulin polymerization, given weekly × 3 as a 1-hour intravenous infusion in patients (pts) with solid tumors [abstract 420]. Proc Am Soc Clin Oncol, 2002.
13. Scfoeffski P, Thate B, Beutel G, Bolte O, Otto D, Hofmann M, Ganser A, Jenner A, Cheverton P, Wanders J, Oguma T, Atsumi R and Satomi M: Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol 15: 671-679, 2004.
14. De Jonge MJA, Van der Gaast A, Planting AST, Van Doom L, Lems A, Boot I, Wanders J, Satomi M and Verweij J: Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res 11: 3806-3813, 2005.
15. Ashizawa T, Asada M, Kobayashi E, Okabe M, Gomi K and Hirata T: Combination effect of navelbine (vinorelbine ditartrate) with cisplatin against murine P388 leukemia and human lung carcinoma xenografts in mice. Anti-Cancer Drugs 4: 577-583, 1993.
16. Otter GM and Sirotnak FM: Effective combination therapy of metastatic murine solid tumors with edatrexate and the vinca alkaloids, vinblastine, navelbine and vindesine. Cancer Chemother Pharmacol 33: 286-290, 1994.
17. Herbst RS, Lynch C, Vasconcelles M, Teicher BA, Strauss G, Elias A, Anderson I, Zacarola P, Dang NH, Leong T, Salgia R and Skarin AT: Gemcitabine and vinorelbine in patients with advanced lung cancer: preclinical studies and report of a phase I trial. Cancer Chemother Pharmacol 48: 151-159, 2001.
18. Wildiers H, Ahmed B, Guetens G, De Boeck G, De Bruijn EA, Landuyt W and Van Osterom AT: Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 40: 284-290, 2004.
19. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y and Suzuki M: Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 94: 200-204, 2003.
20. Mohammad RM, Al-Katib A, Li Y, Pettit GR, Vaitkevicius VK, Joshi U, Adsay V, Majumdar APN and Sarkar FH: An orthotropic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin Cancer Res 4: 887-894, 1998.
21. Mohammad RM, Li Y, Mohamed AN, Pettit GR, Adsay V, Vaitkevicius VK, Al-Katib AM and Sarkar FH: Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma. Pancreas 19: 353-361, 1999.
22. Knick VC, Eberwein DJ and Miller CG: Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. J Natl Cancer Inst 87: 1072-1077, 1995.
23. Fujimoto S and Chikazawa H: Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung cancinoma in vivo. Jpn J Cancer Res 19: 1343-1351, 1998.
24. Bissery MC, Vrignaud P and Lavelle F: Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination. Semin Oncol 22: 3-16, 1995.
25. Han G, Liu Z, Shimoi K and Zhu BT: Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. Cancer Res 65: 387-393, 2005.
26. Forastiere AA, Belliveau JF, Goren MP, Vogel WC, Posner MR and O'Leary GP Jr: Pharmacokinetic and toxicity evaluation of five-day continuous infusion versus intermittent bolus cis-diamminedichloroplatinum(II) in head and neck cancer patients. Cancer Res 48: 3869-3874, 1988.
27. Shipley LA, Brown TJ, Cornpropst JD, Hamilton M, Daniels WD and Culp HW: Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20: 849-855, 1992.
28. Atsumi R, Suzuki W and Hakusui H: Identification of the metabolites of irinotecan, a new derivative of camptothecin, in rat bile and its biliary excretion. Xenobiotica 21: 1159-1169, 1991.
29. Chaudhuri NK, Montag BJ and Heidelberger C: Studies on fluorinated pyrimidines. III. The metabolism of 5-fluorouracil-2-C14 and 5-fluoroorotic-2-C14 acid in vivo. Cancer Res 18: 318-328, 1958.
30. Wiernik PA, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB and Paietta E: Phase I clinical and pharmacokinetic study of taxol. Cancer Res 47: 2486-2493, 1987.
31. De Valeriola D, Brassine C, Gaillard C, Ketier JP, Tomiak E, Van Vreckem A, Fruehling J, Frydman A, Kerger J, Piccart M, Chapelle P and Blanc C: Study of excretion balance, metabolism and protein binding of C14 radiolabelled Taxotere (RP56976, NSC628503) in cancer patients [abstract 2221]. Proc Am Assoc Cancer Res, 1993.